BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16982135)

  • 1. Economics of "essential use exemptions" for metered-dose inhalers under the Montreal Protocol.
    DeCanio SJ; Norman CS
    J Environ Manage; 2007 Oct; 85(1):1-8. PubMed ID: 16982135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The president speaks: prevention is best: lessons from protecting the ozone layer.
    Woodcock A
    Thorax; 2012 Dec; 67(12):1028-31. PubMed ID: 23019254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CFC to HFA transition and its impact on pulmonary drug development.
    Leach CL
    Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of ozone-depleting substances; removal of essential-use designations. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Apr; 70(63):17167-92. PubMed ID: 15806739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to CFC-free beclometasone for asthma.
    Drug Ther Bull; 2008 Jun; 46(6):46-8. PubMed ID: 18525059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albuterol inhalers.
    Gross NJ
    N Engl J Med; 2007 Jun; 356(26):2749; author reply 2749. PubMed ID: 17596614
    [No Abstract]   [Full Text] [Related]  

  • 7. The Montreal Protocol and essential use exemptions.
    D'Souza S
    J Aerosol Med; 1995; 8 Suppl 1():S13-7. PubMed ID: 10150490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition to CFC-free metered dose inhalers--into the new millennium.
    McDonald KJ; Martin GP
    Int J Pharm; 2000 May; 201(1):89-107. PubMed ID: 10867268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ozone layer and metered dose inhalers.
    Boulet LP
    Can Respir J; 1998; 5(3):176-9. PubMed ID: 9707462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CFC Phase-Out and the Chiesi Solution.
    Huchon G; Fabbri LM
    Respiration; 2005; 72 Suppl 1():1-2. PubMed ID: 15915005
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of ozone-depleting substances; removal of essential-use designation (flunisolide, etc.). Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Apr; 75(71):19213-41. PubMed ID: 20391646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Narrowing feedstock exemptions under the Montreal Protocol has multiple environmental benefits.
    Andersen SO; Gao S; Carvalho S; Ferris T; Gonzalez M; Sherman NJ; Wei Y; Zaelke D
    Proc Natl Acad Sci U S A; 2021 Dec; 118(49):. PubMed ID: 34845018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of international environmental agreements in metered-dose inhaler technology changes.
    Forte R; Dibble C
    J Allergy Clin Immunol; 1999 Dec; 104(6):S217-20. PubMed ID: 10588977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential impacts of imposing methyl bromide phaseout on US strawberry growers: a case study of a nomination for a critical use exemption under the Montreal Protocol.
    Norman CS
    J Environ Manage; 2005 Apr; 75(2):167-76. PubMed ID: 15763159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CFCS and the ozone layer.
    Hayman GD
    Br J Clin Pract Suppl; 1997 May; 89():2-9. PubMed ID: 9519506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protecting the ozone layer.
    Munasinghe M; King K
    Finance Dev; 1992 Jun; 29(2):24-5. PubMed ID: 12285661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcohol-based pressurised metered-dose inhalers for use in asthma: a descriptive study.
    Alrasbi M; Sheikh A
    Prim Care Respir J; 2008 Jun; 17(2):111-3. PubMed ID: 18338091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants.
    Hendeles L; Colice GL; Meyer RJ
    N Engl J Med; 2007 Mar; 356(13):1344-51. PubMed ID: 17392304
    [No Abstract]   [Full Text] [Related]  

  • 19. Phaseout of chlorofluorocarbons (CFCs) in metered-dose inhalers. Highlights of the Canadian initial transition strategy.
    D'Urzo AD; D'Urzo DK
    Can Fam Physician; 1999 Jun; 45():1544-6, 1556-7. PubMed ID: 10386220
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of ozone-depleting substances; removal of essential use designations; confirmation of effective date. Direct final rule; confirmation of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Apr; 72(81):20942. PubMed ID: 17520770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.